BioMarin Names New Chief Accounting Officer

An update from BioMarin Pharmaceutical ( (BMRN) ) is now available.

On December 11, 2025, BioMarin Pharmaceutical announced the appointment of Rashmi Ramchandani as its Vice President, Chief Accounting Officer, effective January 19, 2026. Ms. Ramchandani, a seasoned executive with extensive experience in accounting and finance across organizations such as Gilead Sciences, Deloitte, and McKesson Corporation, will also take on the role of principal accounting officer, succeeding Brian Mueller, who remains BioMarin’s CFO. Along with her appointment, the company outlined a comprehensive compensation package for Ms. Ramchandani, reflecting its strategic commitment to onboarding experienced talent to strengthen its financial management and operational foundations.

The most recent analyst rating on (BMRN) stock is a Hold with a $60.00 price target. To see the full list of analyst forecasts on BioMarin Pharmaceutical stock, see the BMRN Stock Forecast page.

Spark’s Take on BMRN Stock

According to Spark, TipRanks’ AI Analyst, BMRN is a Outperform.

BioMarin Pharmaceutical’s strong financial performance and positive earnings call sentiment are the most significant factors contributing to its score. The company’s robust revenue growth and solid cash position are key strengths. Technical analysis and valuation present a mixed picture, with moderate bullish momentum and fair valuation. The absence of corporate events and dividend yield are typical for the industry.

To see Spark’s full report on BMRN stock, click here.

More about BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for rare genetic disorders and conditions with unmet medical needs.

Average Trading Volume: 2,662,251

Technical Sentiment Signal: Sell

Current Market Cap: $9.95B

See more insights into BMRN stock on TipRanks’ Stock Analysis page.